Anti-tumor platinum complexes, their preparation and their therapeutic use
AssigneeSankyo Company, Limited
InventorsYukio Sugimura, Tomoyuki Shibata, Yukiko Kameyama, Kimio Iino, Shigeki Muramatsu, Tomowo Kobayashi, Toshihiko Hashimoto
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I): ##STR1## in which: A and B are separately monoamines or together diamines; and Z is a group of formula (II) or (III): ##STR2## (in which R.sup.1, R.sup.2 and R.sup.7 are various organic groups, n is 0, 1 or 2 and X is a direct carbon-carbon bond or lower alkylene) show valuable anti-tumor activity and may be prepared by reacting an amine-platinum complex with a compound providing the group represented by Z.
Claims11
A compound selected from the group consisting of:
- 1,2-diaminocyclohexaneplatinum(II) 3-[1-(methoxymethoxy)ethyl]-2-oxoazetidin-4-ylacetate;
- 1,2-diaminocyclohexaneplatinum(II) 3-[1-(2-methoxyethoxymethoxy)ethyl]-2-oxoazetidin-4-ylacetate;
- 1,2-diaminocyclohexaneplatinum(II) 3-(1-octanoyloxyethyl)-2-oxoazetidin-4-ylcarboxylate;
- 1,2-diaminocyclohexaneplatinum(II) 3-(1-t-butyldimethylsilyloxyethyl)-2-oxoazetidin-4-ylcarboxylate;
- cis-[trans-(l)-1,2-diaminocyclohexane]platinum(II) {(3S, 4R)-3-[(R)-1-(methoxymethoxy)ethyl]-2-oxoazetidin-4-yl}acetate;
- cis-[trans-(l)-1,2-diaminocyclohexane]platinum(II) {(3S, 4R)-3-[(R)-1-(2-methoxyethoxymethoxy)ethyl]-2-oxoazetidin-4-yl}acetate;
- cis-[trans-(l)-1,2-diaminocyclohexane]platinum(II) {(3S, 4S)-3-[(R)-1-octanoyloxyethyl]-2-oxoazetidin-4-yl}carboxylate;
- and
- cis-[trans-(l)-1,2-diaminocyclohexane]platinum(II) {(3S, 4S)-3-[(R)-1-t-butyldimethylsilyloxyethyl]-2-oxoazetidin-4-yl}carboxylate.
A composition comprising an anti-tumor agent and a pharmaceutically acceptable carrier or diluent, wherein said anti-tumor agent is selected from the group consisting of:
- 1,2-diaminocyclohexaneplatinum(II) 3-[1-(methoxymethoxy)ethyl]-2-oxoazetidin-4-ylacetate;
- 1,2-diaminocyclohexaneplatinum(II) 3-[1-(2-methoxyethoxymethoxy)ethyl]-2-oxoazetidin-4-ylacetate;
- 1,2-diaminocyclohexaneplatinum(II) 3-(1-octanoyloxyethyl)-2-oxoazetidin-4-ylcarboxylate;
- and
- 1,2-diaminocyclohexaneplatinum(II) 3-(1-t-butyldimethylsilyloxyethyl)-2-oxoazetidin-4-ylcarboxylate.
A composition comprising an anti-tumor agent and a pharmaceutically acceptable carrier or diluent, wherein said anti-tumor agent is selected from the group consisting of:
- cis-[trans-(l)-1,2-diaminocyclohexane]platinum(II) {(3S, 4R)-3-[(R)-1-(methoxymethoxy)ethyl]-2-oxoazetidin-4-yl}acetate;
- cis-[trans-(l)-1,2-diaminocyclohexane]platinum(II) {(3S, 4R)-3-[(R)-1-(2-methoxyethoxymethoxy)ethyl]-2-oxoazetidin-4-yl}acetate;
- cis-[trans-(l)-1,2-diaminocyclohexane]platinum(II) {(3S, 4S)-3-[(R)-1-octanoyloxyethyl]-2-oxoazetidin-4-yl}carboxylate;
- and
- cis-[trans-(l)-1,2-diaminocyclohexane]platinum(II) {(3S, 4S)-3-[(R)-1-t-butyldimethylsilyloxyethyl]-2-oxoazetidin-4-yl}carboxylate.
Dependencies are inferred from the claim text.